A affected person of mine, a veteran who had tried to give up smoking for over a decade, advised me that after he began a GLP-1 drug for his diabetes, he misplaced curiosity in cigarettes. He didn’t use a patch. He didn’t set a give up date. He merely misplaced curiosity. It occurred with out effort.
One other affected person on considered one of these medicine for weight reduction advised me that alcohol had misplaced its pull – after years of failed makes an attempt to give up.
Individuals combating many addictions, starting from opioids to playing, are reporting similar experiences in clinics, on social media and round dinner tables. None of them began these medicine to give up. This sample of individuals dropping their cravings throughout a broad vary of addictive substances has no precedent in drugs.
However my sufferers have been giving me an vital clue. Individuals taking GLP-1 medicine usually speak about “meals noise” vanishing: the fixed psychological chatter about meals that dominated their days merely goes quiet. However my sufferers have been reporting that it wasn’t simply meals: They have been noticing that the preoccupation with smoking, ingesting and utilizing medicine that drives individuals again regardless of their finest intentions to cease was going quiet too.
As a physician whose sufferers are sometimes on GLP-1 medicine, and as a scientist who works on answering pressing public health questions – from long COVID to medication safety – I noticed an issue hiding in plain sight: Many addictions don’t have any authorised therapy. The few drugs that exist are massively underutilized, and none works throughout all substances. The concept that a drug already taken by hundreds of thousands would possibly do what no dependancy therapy has executed earlier than was too vital to disregard.
My workforce and I got down to take a look at whether or not GLP-1 medicine – drugs like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), originally developed for diabetes after which approved for obesity – may do what no present dependancy therapy does: curb craving itself.
Our proof strongly suggests they can.
Organic foundation of cravings
The hormone that these medicine mimic – GLP-1 – isn’t solely produced within the intestine. Additionally it is lively within the mind, the place the receptors it binds to cluster in areas governing reward, motivation and stress – the identical circuitry that gets hijacked by addiction. At therapeutic doses, GLP-1 medicine cross the blood-brain barrier and dampen dopamine signaling within the mind’s core reward middle, making addictive substances less rewarding.
GLP-1 medicine appear to inhibit cravings for a number of totally different substances in a number of animal fashions. For example, rodents given GLP-1 medicine drink less alcohol, self-administer less cocaine and show less interest in nicotine. When researchers gave semaglutide to inexperienced vervet monkeys – primates that voluntarily drink alcohol very like people do – the animals drank less with out exhibiting indicators of nausea or adjustments in water consumption. This implies the drug lowered the reward worth of alcohol fairly than making the animals really feel sick.
From animals to individuals
To search out out whether or not these medicine have a similar effect on people, we turned to the digital well being information of greater than 600,000 sufferers with Kind 2 diabetes on the U.S. Division of Veterans Affairs – one of many largest well being care databases on the planet.
We designed a examine that utilized the rigor of randomized controlled trials – the gold commonplace in drugs – to real-world information. We in contrast individuals who began GLP-1 medicine to individuals who didn’t, adjusting for variations in well being historical past, demographics and different components, and adopted each teams for 3 years.
My workforce and I requested two questions: For individuals already combating dependancy, did the medicine scale back overdoses, drug-related hospitalizations and deaths? And for individuals with no prior substance use dysfunction, did GLP-1 medicine scale back their threat of growing one throughout all main addictive substances: alcohol, opioids, cocaine, hashish and nicotine?
What we discovered was hanging. Within the group already combating dependancy, there have been 50% fewer deaths because of substance use amongst these taking GLP-1 medicine in contrast with those that weren’t. We additionally discovered 39% fewer overdoses, 26% fewer drug-related hospitalizations and 25% fewer suicide makes an attempt. Over three years, this translated to roughly 12 fewer critical occasions in complete per 1,000 individuals utilizing GLP-1 medicine – together with two fewer deaths.
Reductions of this magnitude are uncommon in dependancy drugs – and what’s exceptional is that the discovering got here from medicine initially designed for diabetes, later repurposed for weight problems and by no means supposed to deal with dependancy.
The medicine additionally appeared to stop dependancy from growing within the first place. Amongst individuals with no prior substance use dysfunction, these taking GLP-1 medicine had an 18% decrease threat of growing alcohol use dysfunction, a 25% decrease threat of opioid use dysfunction and an roughly 20% decrease threat of cocaine and nicotine dependence. Over three years, this translated to roughly six to seven fewer new diagnoses per 1,000 GLP-1 customers.
With tens of hundreds of thousands of individuals already utilizing GLP-1 medicine, the reductions in deaths, overdoses, hospitalizations and new diagnoses may translate into 1000’s of prevented critical occasions every year.
Converging proof
Our findings align with a rising physique of proof.
A Swedish nationwide examine of 227,000 individuals with alcohol use dysfunction discovered that these taking GLP-1 medicine had 36% lower risk of alcohol-related hospitalizations. That is greater than double the 14% discount that the identical examine discovered with naltrexone, which was the best-performing treatment authorised for therapy of alcohol use dysfunction in that evaluation. Different observational research have linked GLP-1 medicine to decrease charges of new and recurring alcohol use disorder, reduced diagnoses and relapse in cannabis use disorder, fewer health care visits for nicotine dependence and lower risk of opioid overdose.
In the meantime, randomized managed trials that directly test whether these drugs help individuals with dependancy additionally present promise. In a single trial, semaglutide reduced both craving and alcohol consumption in individuals with alcohol use dysfunction. In one other, dulaglutide reduced drinking. Greater than a dozen additional trials are already underway or actively enrolling, and several other extra are deliberate.
The way forward for dependancy therapy
GLP-1 medicine are the primary sort of treatment to indicate potential profit throughout a number of substance varieties concurrently. And in contrast to present dependancy drugs, that are prescribed by specialists and stay vastly underused, GLP-1 medicine are already prescribed at enormous scale by main care medical doctors. The supply system to achieve hundreds of thousands of sufferers already exists.
The consistency of GLP-1 effectiveness throughout alcohol, opioids, cocaine, nicotine and hashish suggests these medicine might act on a shared vulnerability underlying dependancy – not on any single substance pathway. If confirmed, that may characterize a basic shift in how society understands dependancy and the way medical doctors deal with it.
Some unanswered questions stay, although, about how these medicine would have an effect on dependancy. Many individuals who take GLP-1 medicine to deal with weight problems or diabetes discontinue them; afterward, their urge for food typically returns and they regain the weight they lost. Whether or not the identical rebound would happen with dependancy, and what it could imply for somebody in restoration to face the roar of craving once more, is unknown. Neither is it clear whether or not the advantages persist over years of steady use, or whether or not the mind adapts in ways in which dampen these results.
Additionally, as a result of GLP-1 medicine engage the brain’s reward circuitry – the identical system that governs not simply craving however on a regular basis motivation – extended use may, in concept, dampen motivational drive in some individuals. Whether or not which may have an effect on real-world outcomes, corresponding to initiative, aggressive drive or efficiency at work, stays an open query.
What comes subsequent
GLP-1 medicine haven’t been authorised for dependancy, and there’s not but sufficient proof to prescribe them solely for that objective. However for hundreds of thousands of individuals already weighing whether or not to begin a GLP-1 drug for diabetes, weight problems or one other authorised indication, it’s another issue price contemplating.
A affected person residing with diabetes who can also be making an attempt to give up smoking would possibly fairly select a GLP-1 drug over one other glucose-lowering treatment, not as a result of it’s authorised for smoking cessation, however as a result of it might assist them give up, a profit that different diabetes medicine don’t supply. Equally, for individuals residing with weight problems who additionally wrestle with alcohol, the potential for profit past weight reduction might be another reason to contemplate a GLP-1 drug.
If extra trials verify that they successfully curb cravings throughout addictive substances, these medicine may start to shut some of the consequential therapy gaps in drugs. And probably the most promising lead in dependancy in many years can have come not from a deliberate search however from sufferers reporting a profit nobody anticipated. Like my affected person who give up smoking after a lifetime of making an attempt, it occurred with out effort.